SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Preventive Visit — Booker T. Washington

PatientBooker T. Washington
Date of birth1967-04-05
IdentifiersMRN HR-NI017-SYN; SSN (made up) 000-17-2284
Document date2026-09-21
AuthorLorraine Whitfield, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Periodic preventive visit; no new complaints. [S]

History of Present Illness

Mr. Washington comes for his periodic preventive visit. He completed the health risk assessment before the visit. The back strain from August cleared in about ten days with heat, walking, and acetaminophen, and he has taken no NSAIDs since. His home blood pressures over the past two weeks have averaged in the low 120s systolic. His headaches have not returned and his concentration is better than in the spring, although he still tires by evening on travel days. He has had no emergency visits or hospital stays. He takes his four blood pressure and kidney medicines and his statin from a weekly organizer and has added no over-the-counter medicines or supplements. [S]

ElementDetail
VisitPeriodic adult preventive visit, age 59
Interval historyLumbar strain in August, resolved without NSAIDs or imaging
Blood pressure at homeAveraging in the low 120s systolic
MedicinesAdherent with a weekly organizer; no NSAIDs or new over-the-counter products
Active conditionsHypertensive chronic kidney disease stage G3b A3, hypertensive retinopathy, mild anemia of chronic kidney disease, and hyperlipidemia
Functional statusIndependent in all activities; tires by evening on travel days

Health risk assessment. Completed by the patient before the visit and reviewed during the visit. [S]

DomainFinding
Self-rated healthGood, and better than in the spring
PsychosocialLives with his spouse; close family and colleagues; work and travel are heavy, and he feels the strain but not low mood
TobaccoNever smoker
AlcoholA drink a few times a year; AUDIT-C score 1
Physical activityWalks 20 to 30 minutes on most days at home, less when traveling; about 120 minutes a week
NutritionLow-sodium meals at home; chooses lower-sodium dishes when eating on the road, with mixed success
SleepAbout six hours on work nights; no snoring or daytime sleepiness reported
Activities of daily livingIndependent in all activities of daily living
Instrumental activities of daily livingManages his own medicines, finances, correspondence, and travel
Home and travel safetySmoke detectors working; wears a seat belt; no firearms in the home
Hearing and visionReading glasses; dilated eye examination in May; no hearing concerns

Review of Systems

SystemResultFinding
ConstitutionalPositiveTires by evening on travel days; weight stable; no fever or night sweats
EyesNegativeNo new blurring, floaters, or loss of vision
Ears, nose, mouth, and throatNegativeNo hearing loss or hoarseness
CardiovascularNegativeNo chest pain, palpitations, orthopnea, or ankle swelling
RespiratoryNegativeNo cough or breathlessness
GastrointestinalNegativeOccasional indigestion when traveling, unchanged; no difficulty swallowing, blood in the stool, or black stool
GenitourinaryNegativeNighttime urination once; no weak stream, dysuria, or blood in the urine
MusculoskeletalNegativeBack pain from August resolved; no joint pain
IntegumentaryNegativeNo rashes or genital symptoms on dapagliflozin
NeurologicalNegativeHeadaches resolved; concentration improved; no weakness, numbness, or dizziness on standing
PsychiatricNegativeMood steady; PHQ-9 score 2
EndocrineNegativeNo polyuria, polydipsia, or heat or cold intolerance
HematologicNegativeNo easy bruising or bleeding

13 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Amlodipine 10 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-05-04activeS
Losartan 50 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-05-04 to 2026-05-11completedS
Losartan 100 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-05-11activeS
Dapagliflozin 10 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-05-11activeS
Chlorthalidone 25 mg oral tablet, one-half tablet (12.5 mg) by mouth dailyOne-half tablet by mouth dailyOral route2026-06-01activeS
Atorvastatin 20 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-05-04activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-09-21Body height170cmS
2026-09-21Body weight70.4kgS
2026-09-21Body mass index (BMI) [Ratio]24.4kg/m2S
2026-09-21Systolic blood pressure122mm[Hg]S
2026-09-21Diastolic blood pressure76mm[Hg]S
2026-09-21Heart rate72/minS
2026-09-21Respiratory rate14/minS
2026-09-21Body temperature36.6CelS
2026-09-21Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-09-21Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]2{score}S
2026-09-21Total score [AUDIT-C]1{score}S

Physical Exam

Vital signs recorded on 2026-09-21; see the Vital Signs section. [S]

SystemFinding
ConstitutionalAlert, well-appearing, and articulate; weight 70.4 kg, BMI 24.4
EyesUndilated funduscopy shows arteriolar narrowing and arteriovenous nicking, unchanged; no hemorrhages, exudates, or disc swelling
Ears, nose, and throatCanals and tympanic membranes normal; oropharynx clear
NeckNo thyroid enlargement or nodes; no carotid bruits
CardiovascularRegular rhythm, rate 72; apical impulse not displaced; no murmur; pedal pulses normal; no edema
RespiratoryClear to auscultation bilaterally
AbdomenSoft and non-tender; no masses or renal bruit
MusculoskeletalFull, pain-free lumbar range of motion; no paraspinal spasm
SkinNo rashes or suspicious lesions
NeurologicalAlert and oriented; strength, sensation, and gait normal
PsychiatricEuthymic and engaged; judgment and insight intact

Problems

ProblemClinical statusVerificationCodeProvenance
Severe hypertension with hypertensive kidney disease; synthetic modern diagnosis linked to the documented 1915 blood pressure of 220/150activeconfirmed I12.9S — Synthetic active diagnosis for the teaching episode; the 1915 findings remain D and the retrospective diagnosis remains R.
Chronic kidney disease stage G3b A3 (severely increased albuminuria), attributed to hypertensive nephrosclerosisactiveconfirmed N18.32S — Synthetic diagnosis supported by small echogenic kidneys and albuminuria; linked to the documented 1915 diagnosis of Bright's disease.
Hypertensive retinopathy, both eyes, without papilledemaactiveconfirmed H35.033S — Synthetic funduscopic finding that echoes the documented failing vision.
Mild anemia of chronic kidney disease, iron replete; monitoractiveconfirmed D63.1S — Synthetic finding from the baseline hemoglobin and iron studies.
Hyperlipidemiaactiveconfirmed E78.5S — Synthetic finding from the baseline LDL cholesterol.
Acute lumbar muscle strain after lifting, resolved without NSAIDs or imagingresolvedconfirmed S39.012AS — Synthetic intercurrent illness at an unscheduled visit; it does not echo a documented illness.

Assessment and Plan

Personalized prevention plan. A written copy was given to the patient. [S]

ServiceStatusDetail
Influenza vaccineCompleted todayThis season's vaccine given today
Recombinant zoster vaccineCompleted todayDose 1 of 2 given today; dose 2 due in two to six months
COVID-19 vaccineDueDiscussed; he plans to get this season's vaccine at his pharmacy
RSV vaccineDueDiscussed because chronic kidney disease increases his risk of severe RSV illness; he will decide at the pharmacy visit
Pneumococcal vaccineUp to datePCV20 given in May; no further doses needed
Hepatitis B vaccineUp to dateTwo-dose HepB-CpG series completed in June
Tetanus boosterUp to dateTdap seven years ago; next booster due in about three years
Colorectal cancer screeningReferredNo prior screening on record; he chose colonoscopy. Referral sent with a request for a polyethylene glycol preparation and no sodium phosphate preparation, because of his kidney disease; hold dapagliflozin and chlorthalidone on the preparation day
Prostate cancer screeningOrderedShared decision-making about benefits, false positives, and overdiagnosis, including the higher prostate cancer risk among Black men described in the USPSTF statement. He chose PSA testing; added to the October blood draw
Hepatitis C and HIV screeningOrderedOne-time screening offered to all adults in these age ranges, not based on any individual risk; no prior result on record; added to the October blood draw
Blood pressure, cholesterol, and diabetes screeningUp to dateTreated hypertension; on statin therapy; HbA1c 5.4 percent in May
Depression screeningCompleted todayPHQ-9 score 2
Unhealthy alcohol use screeningCompleted todayAUDIT-C score 1
Tobacco useCompleted todayNever smoker
Physical activity and dietCompleted todayCounseled to reach 150 minutes of walking a week and to keep sodium below 2 g a day when traveling
Lung cancer and abdominal aortic aneurysm screeningNot indicatedNever smoker
Eye examinationUp to dateDilated examination in May; repeat yearly for hypertensive retinopathy

Immunizations given today: Influenza vaccine, 2026-2027 season; Recombinant zoster vaccine, dose 1 of 2 [S]

Guideline basis: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); CMID: Clinical Monitoring Intelligence Database, hypertension and chronic kidney disease monographs (2026); USPSTF A and B Recommendations (2026); Colorectal Cancer: Screening (2021); Prostate Cancer: Screening (2018)

Follow-up: Colonoscopy referral sent; PSA and hepatitis C and HIV screening with the October blood draw. Zoster vaccine dose 2 in two to six months. Six-month blood pressure and kidney review in October. Next preventive visit in one year. Next scheduled visit 2026-10-26: six-month blood pressure and chronic kidney disease review. [S]

Advance Care Planning

Voluntary advance care planning discussion of about 20 minutes, with his consent, prompted by his chronic kidney disease. He has named a health care agent and has a written health care directive; a copy is now in the chart. He wants full treatment for reversible illness, including hospital care. He asked to learn more about the options if his kidney function falls further, including dialysis and conservative care, and that discussion will continue with nephrology. He will review these wishes with his agent. [S]